Harbin Medisan Pharmaceutical Co., Ltd. (SHE:002900)
China · Delayed Price · Currency is CNY 12.22
-0.04 (-0.33%)
Feb 27, 2026, 3:04 PM CST
SHE:002900 Revenue
Harbin Medisan Pharmaceutical had revenue of 167.53M CNY in the quarter ending September 30, 2025, a decrease of -46.83%. This brings the company's revenue in the last twelve months to 874.60M, down -20.70% year-over-year. In the year 2024, Harbin Medisan Pharmaceutical had annual revenue of 1.13B, down -4.58%.
Revenue (ttm)
874.60M
Revenue Growth
-20.70%
P/S Ratio
4.32
Revenue / Employee
346.79K
Employees
2,522
Market Cap
3.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.13B | -54.31M | -4.58% |
| Dec 31, 2023 | 1.19B | 158.37M | 15.40% |
| Jan 1, 2023 | 1.03B | 82.61M | 8.73% |
| Jan 1, 2022 | 945.80M | -393.08M | -29.36% |
| Dec 31, 2020 | 1.34B | -763.18M | -36.31% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PKU HealthCare Corp.,Ltd. | 1.76B |
| Nanjing Well Pharmaceutical Group | 1.31B |
| Huaren Pharmaceutical | 1.26B |
| Shaanxi Panlong Pharmaceutical Group Limited By Share | 1.10B |
| Hunan Hansen Pharmaceutical | 1.05B |
| Anhui Sunhere Pharmaceutical Excipients | 934.72M |
| Zhejiang Shengda Bio-Pharm | 839.82M |
| Zhejiang Cheng Yi Pharmaceutical | 790.86M |